Perspective: Treatment for disease modification in chronic neurodegeneration

17Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Symptomatic treatments are available for Parkinson’s disease and Alzheimer’s disease. An unmet need is cure or disease modification. This review discusses possible reasons for negative clinical study outcomes on disease modification following promising positive findings from experimental research. It scrutinizes current research paradigms for disease modification with antibodies against pathological protein enrichment, such as α-synuclein, amyloid or tau, based on post mortem findings. Instead a more uniform regenerative and reparative therapeutic approach for chronic neurodegenerative disease entities is proposed with stimulation of an endogenously existing repair system, which acts independent of specific disease mechanisms. The repulsive guidance molecule A pathway is involved in the regulation of peripheral and central neuronal restoration. Therapeutic antagonism of repulsive guidance molecule A reverses neurodegeneration according to experimental outcomes in numerous disease models in rodents and monkeys. Antibodies against repulsive guidance molecule A exist. First clinical studies in neurological conditions with an acute onset are under way. Future clinical trials with these antibodies should initially focus on well characterized uniform cohorts of patients. The efficiency of repulsive guidance molecule A antagonism and associated stimulation of neurogenesis should be demonstrated with objective assessment tools to counteract dilution of therapeutic effects by subjectivity and heterogeneity of chronic disease entities. Such a research concept will hopefully enhance clinical test strategies and improve the future therapeutic armamentarium for chronic neurodegeneration.

References Powered by Scopus

Dementia prevention, intervention, and care

4358Citations
N/AReaders
Get full text

Alzheimer's disease

1897Citations
N/AReaders
Get full text

Diagnosis and Treatment of Parkinson Disease: A Review

1850Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Pharmacological Potential of Adenosine A<inf>2A</inf> Receptor Antagonists for Treating Parkinson’s Disease

34Citations
N/AReaders
Get full text

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice

30Citations
N/AReaders
Get full text

Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?

13Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Müller, T., Mueller, B. K., & Riederer, P. (2021, April 1). Perspective: Treatment for disease modification in chronic neurodegeneration. Cells. MDPI. https://doi.org/10.3390/cells10040873

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

67%

Researcher 3

25%

Professor / Associate Prof. 1

8%

Readers' Discipline

Tooltip

Immunology and Microbiology 5

36%

Neuroscience 4

29%

Agricultural and Biological Sciences 3

21%

Psychology 2

14%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free